Jula Inrig, Travere R&D EVP, sells $2.78m in shares By Investing.com

Jula Inrig, Executive Vice President, Head of Research & Development & Chief Medical Officer at Travere Therapeutics, Inc. (), sold a total of 44,674 shares of common stock on September 15, 2026, for a total value of $2,785,020. The shares were sold at prices ranging between $62.0167 and $65.31. Prior to these sales, Ms. Inrig also acquired 32,395 shares through the exercise of employee stock options.

The sales, totaling 44,674 shares, were executed at various prices. Specifically, 25,390 shares were sold with a weighted average price of $62.0167, within a range of $61.40 to $62.39. An additional 17,284 shares were sold at a weighted average price of $62.6242, with prices ranging from $62.40 to $63.365. Further sales included 1,600 shares at a weighted average price of $63.685, within a range of $63.58 to $63.86, and 400 shares at $65.31. These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on June 16, 2026.

Earlier on the same day, Ms. Inrig acquired 32,395 shares of Travere Therapeutics common stock by exercising employee stock options at a price of $8.93 per share, totaling $289,287. The employee stock option has a vesting schedule, with one-fourth of the shares becoming exercisable on the first anniversary of January 31, 2024, and the remainder vesting in 36 equal monthly installments thereafter. Investors seeking deeper insights into Travere’s financial health and growth prospects can access the comprehensive Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other US equities.

Following these reported transactions, Ms. Inrig beneficially owns 100,491 shares of Travere Therapeutics common stock.

In other recent news, Travere Therapeutics reported second-quarter revenue of $169.6 million, surpassing Wall Street’s projection of $160.66 million. The revenue boost was primarily driven by the strong demand for its kidney drug, FILSPARI, which saw sales rise approximately 96% from the previous year to $141.1 million. This quarter marked the first full period with FILSPARI available for both IgA nephropathy and the newly launched FSGS. U.S. net product sales reached $161.4 million, with FILSPARI contributing significantly. Additionally, the company recorded $8.2 million in licensing and collaboration revenue. In light of these developments, Stifel raised its price target for Travere Therapeutics to $62 from $43, maintaining a Hold rating. The firm highlighted the strong performance of FILSPARI in its first full quarter following the FSGS launch. Travere Therapeutics concluded the quarter with approximately $489.2 million in cash, equivalents, and marketable securities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.